Literature DB >> 28000525

Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment.

Laura C Cappelli1, Jarushka Naidoo2, Clifton O Bingham1, Ami A Shah1.   

Abstract

Entities:  

Keywords:  cancer; immune checkpoint inhibitors; immunotherapy; inflammatory arthritis

Mesh：

Substances：

Year:  2017        PMID： 28000525     DOI： 10.2217/imt-2016-0117

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  8 in total

1.  Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events.

Authors:  Jemima Albayda; Clifton O Bingham; Ami A Shah; Ronan J Kelly; Laura Cappelli
Journal:  Rheumatology (Oxford)       Date:  2018-04-01       Impact factor: 7.580

2.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

3.  Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.

Authors:  Amy Cunningham-Bussel; Jiaqi Wang; Lauren C Prisco; Lily W Martin; Kathleen M M Vanni; Alessandra Zaccardelli; Mazen Nasrallah; Lydia Gedmintas; Lindsey A MacFarlane; Nancy A Shadick; Mark M Awad; Osama Rahma; Nicole R LeBoeuf; Ellen M Gravallese; Jeffrey A Sparks
Journal:  Arthritis Rheumatol       Date:  2022-01-25       Impact factor: 10.995

4.  Successful use of adalimumab in immune checkpoint inhibitor-associated inflammatory arthritis.

Authors:  Anuoluwapo R Oke; Matthew Wheater; Ioannis Karydis; Dinny Wallis
Journal:  Rheumatol Adv Pract       Date:  2018-01-30

5.  Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.

Authors:  Jan Leipe; Xavier Mariette
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

Review 6.  Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events.

Authors:  Marianne Davies; Emily A Duffield
Journal:  Immunotargets Ther       Date:  2017-08-24

Review 7.  Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.

Authors:  Juwhan Choi; Sung Yong Lee
Journal:  Immune Netw       Date:  2020-02-17       Impact factor: 6.303

Review 8.  Nanomaterials for the Diagnosis and Treatment of Inflammatory Arthritis.

Authors:  Seyedeh Maryam Hosseinikhah; Mahmood Barani; Abbas Rahdar; Henning Madry; Rabia Arshad; Vahideh Mohammadzadeh; Magali Cucchiarini
Journal:  Int J Mol Sci       Date:  2021-03-18       Impact factor: 6.208
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.